NCT04017546 2024-09-19
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
Cyclacel Pharmaceuticals, Inc.
Phase 1 Completed
Clinical Trials
3 trialsNCT02552953 2024-05-31
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
Cyclacel Pharmaceuticals, Inc.
Phase 1 Completed
NCT03739554 2024-01-25
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
Cyclacel Pharmaceuticals, Inc.
Phase 1 Completed